Biotech financing update: June-August 2022

With a total of £1.5 billion for the first three quarters of 2022, UK-based biotechs are on track for their fourth best year, ever.

Venture financings are holding up by historical standards but have progressively reduced quarter on quarter throughout the year. The public markets continue to confound, however, with no new listings but some large follow-on financings on NASDAQ, raising the overall quarterly takings from all sources to £578 million. This is the best quarter of 2022.